Mode
Text Size
Log in / Sign up

Oligometastatic recurrence

Part of Cancer

1 published article · Updated continuously

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Cancer

Related studies from across the Cancer family.

SABR Protocol Deviations Linked to Poorer Survival in Oligometastatic Head and Neck Cancer
ENT (Otolaryngology) RCT
SABR Protocol Deviations Linked to Poorer Survival in Oligometastatic Head and Neck Cancer Major protocol deviations cut survival time for head and neck cancer patients
This exploratory analysis of a randomized phase 2 trial (GORTEC 2014-04) in 69 patients with oligometastatic head and neck cancer found that…
Strict radiation quality checks linked to better survival for head and neck cancer patients. Minor or major errors during treatment reduced …
Curative-intent local therapy linked to improved survival in isolated contralateral axillary breast metastasis
Oncology Cohort
Curative-intent local therapy linked to improved survival in isolated contralateral axillary breast metastasis Local therapy linked to better survival in advanced breast cancer patients with specific metastases
This retrospective cohort study of 1110 patients across two tertiary centers compared outcomes in isolated contralateral axillary metastasis…
Patients with specific breast cancer spread to the opposite armpit survived longer when receiving surgery or radiation compared to systemic …
Lu-PSMA-617 reduces disease progression versus deferred ADT in oligometastatic HSPC in phase 2 trial
Oncology RCT
Lu-PSMA-617 reduces disease progression versus deferred ADT in oligometastatic HSPC in phase 2 trial Can a targeted radiation drug delay prostate cancer progression without hormone therapy?
A phase 2 randomized controlled trial of 58 men with biochemically recurrent oligometastatic hormone-sensitive prostate cancer found Lu-PSMA…
A targeted radiation drug delayed prostate cancer progression by 20 months in early-stage patients without requiring hormone therapy first.
SMART radiation shows 90% 4-year local control in small oligometastatic abdominopelvic cohort
Urology Phase I
SMART radiation shows 90% 4-year local control in small oligometastatic abdominopelvic cohort Can targeted radiation safely treat small, recurring cancer spots in the abdomen?
A single-arm Phase 1/2 trial in 10 patients with solid tumor abdominopelvic oligometastases found Stereotactic MR-Guided Adaptive Radiation …
Targeted radiation safely controlled small recurring cancer spots in the abdomen for 90% of patients with only mild side effects after four …
Patient-to-patient communication reduces fear of cancer recurrence after laryngectomy in RCT
Psychiatry RCT
Patient-to-patient communication reduces fear of cancer recurrence after laryngectomy in RCT Patient-led support sessions reduced fear of cancer returning after throat surgery
An 85-patient randomized trial found a patient-to-patient communication model (PG) reduced fear of cancer recurrence (FCR) more than standar…
Patients who met with others after throat surgery saw their fear of cancer returning drop by 38%, outperforming both standard care and psych…
Phase 3 Study of Lutetium (177Lu) Vipivotide Tetraxetan in OMPC Patients
Drug Pipeline Phase III
Phase 3 Study of Lutetium (177Lu) Vipivotide Tetraxetan in OMPC Patients Can a new treatment delay prostate cancer from spreading further?
Phase 3 trial evaluates lutetium (177Lu) vipivotide tetraxetan for oligometastatic prostate cancer. Primary outcome: Metastasis Free Surviva…
A new prostate cancer treatment aims to delay cancer spread and spare men from intensive hormone therapy while preserving their quality of l…